RET Expression and Its Correlation with Clinicopathologic Data in Papillary Thyroid Carcinoma

• Main Authors: Ante Punda, Vladimir Bedeković, Ana Barić, Mirko Kontić, Zaviša Čolović, Lucija Vanjaka Rogošić, Hrvoje Punda, Nenad Kunac, Leo Grandić, Valdi Pešutić Pisac
• Format: Article
• Language: English
• Published: Sestre Milosrdnice University hospital, Institute of Clinical Medical Research 2018-01-01
• Series: Acta Clinica Croatica
• Subjects: Mutation; Thyroid cancer, papillary; Chernobyl nuclear accident; Lymphatic metastasis; Radiation
• Online Access: http://hrcak.srce.hr/file/317904
• ISSN: 0353-9466; 1333-9451

The purpose of this study was to analyze the possible prognostic value of RET mutation in papillary thyroid carcinoma and its incidence in the past few decades in our population, due to the increasing incidence of papillary thyroid carcinoma. The present study included 180 patients operated for papillary thyroid carcinoma. The clinical and histopathologic characteristics were analyzed. Paraffin sections of the selected histologic slides were cut again and immunohistochemically stained by the Clone 3F8 P (HIER) from Novocastra (Vision Bio Systems Europe, Newcastle upon Tyne, UK) monoclonal antibody to RET oncoprotein. Univariate analysis indicated sex (p=0.01), histologic subtype (p=0.075) and capsular invasion (p=0.010) to be statistically significant predictors of lymph node metastases, whereas age (p=0.796), tumor size (p=0.556) and intraglandular dissemination (p=0.131) showed no such correlation. The presence of RET mutation (p=0.704) was not a statistically significant predictor of the tumor metastasizing potential. RET mutation (p=0.500) showed no statistically significant correlation with papillary thyroid carcinoma classifed into prognostic groups according to clinicopathologic features either. RET mutation was detected in 30% of 180 papillary thyroid carcinomas. This is the first large study demonstrating that RET mutation incidence in papillary thyroid carcinoma in Croatian population is consistent with the classic distribution of sporadic cases, despite the increased prevalence of papillary thyroid carcinoma in the past few decades.